NEW YORK, Oct. 23 - Incyte Genomics and Genentech have struck a licensing deal that covers patents covering therapeutic antibodies to four proteins discovered by Incyte, the companies said on Tuesday.
Under terms of the agreement, Incyte is entitled to receive clinical development milestone payments for the antibodies and royalties if any are commercialized.
Financial terms of the agreement and the intended clinical uses of the four antibodies were not disclosed.
Separately on Tuesday, Incyte, of Palo Alto, Calif., said it has rescheduled the release of its third-quarter financial statement to Oct. 25. The company will hold a conference call for investors at 9:30 a.m. PDT.
The release date, originally scheduled for Oct. 24, was changed to avoid scheduling conflicts, Incyte said.
Last week, Incyte was sued by Invitrogen in a patent dispute over Invitrogen’s SuperScript form of RNAse H minus reverse transcriptase, which the company said was sold to Incyte under a research-use-only license.
As GenomeWeb reported on Thursday, Carlsbad, Calif.-based Invitrogen said it seeks to have Incyte stop using the product without a commercial license and to stop buying the product from unlicensed third parties.